Landau-Kleffner Syndrome Summary

38 relevant articles (3 outcomes, 3 trials/studies) found for this Disease

Description: A syndrome characterized by the onset of isolated language dysfunction in otherwise normal children (age of onset 4-7 years) and epileptiform discharges on ELECTROENCEPHALOGRAPHY. Seizures, including atypical absence (EPILEPSY, ABSENCE), complex partial (EPILEPSY, COMPLEX PARTIAL), and other types may occur. The electroencephalographic abnormalities and seizures tend to resolve by puberty. The language disorder may also resolve although some individuals are left with severe language dysfunction, including APHASIA and auditory AGNOSIA. (From Menkes, Textbook of Child Neurology, 5th ed, pp749-50; J Child Neurol 1997 Nov;12(8):489-495)

Also Known As: Aphasia, Epileptic, Acquired; Landau-Kleffner Acquired Epileptiform Aphasia; Acquired Epileptic Aphasia; Acquired Epileptic Aphasias; Aphasias, Acquired Epileptic Show All >>

Key Drugs and Agents for Landau-Kleffner Syndrome

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:

Intravenous Immunoglobulins (IVIG) : 1 outcome in 5 results : FDA 1
Adrenal Cortex Hormones (Corticosteroids) : 1 outcome in 3 results : IBA
Immunoglobulins (Immunoglobulin) : 1 outcome in 2 results : IBA
Glucose (Dextrose) : 2 studies in 4 results : FDA 183 Generic
Anticonvulsants (Antiepileptic Drugs) : 3 results : IBA
Vigabatrin : 2 results : IBA
gamma-Globulins (gamma-Globulin) : 2 results : IBA
Nerve Growth Factor (NGF) : 1 result : IBA
Fluorodeoxyglucose F18 (Fludeoxyglucose F 18) : 1 result : FDA 2
Brain-Derived Neurotrophic Factor (BDNF) : 1 result : IBA

Show All >>

Diseases Related to Landau-Kleffner Syndrome

Show All >>

Key Therapies for Landau-Kleffner Syndrome

Efficacy Chart >>

Aftercare (After-Treatment) : 1 outcome in 1 result
Sign Language : 1 study in 4 results